Literature DB >> 25533817

A scoring system for prediction of early recurrence after liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma.

Honggang Qian1, Meng Wei1, Hui Qiu1, Jianhui Wu1, Bonan Liu1, Ang Lyu1, Qiao Liu1, Chengpeng Li1, Jiahua Leng1, Ji Zhang1, Chunyi Hao2.   

Abstract

BACKGROUND: The management of Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) is controversial due to the early recurrence after curative hepatectomy, and many variables were related to the prognosis. The purpose of this study was to predict the tumor recurrence in early postoperative period of the patients with BCLC stage B HCC.
METHODS: From January 2004 to January 2012, 104 patients with BCLC stage B HCC underwent hepatectomy. Clinicopathological factors and follow-up data were statistically analyzed to establish a predicting scoring system.
RESULTS: The overall survival rates for one, three, and five years were 69.2%, 52.7%, and 42.3%, and the disease-free survival rates for one, three, and five years were 52.9%, 47.3%, and 37.5%, respectively. The multiple factors analysis showed that the micro-vessel invasion, lymph nodes metastasis, multiple lesions, and the high expression of HMGB1 were independent factors (P < 0.05). A scoring system was established to predict the early recurrence within one year after the surgery for BCLC stage B HCC, according to the analysis results with a specificity of 85.1% and a sensitivity of 80.3%.
CONCLUSION: Variant clinicopathological factors were associated with early postoperative recurrence for BCLC stage B HCC and recurrence early after hepatectomy was more likely in patients with a higher score of the scoring system.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25533817

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  3 in total

Review 1.  Review on the Applications and Molecular Mechanisms of Xihuang Pill in Tumor Treatment.

Authors:  Qiujun Guo; Jinyin Lin; Rui Liu; Yebo Gao; Shulin He; Xinyao Xu; Baojin Hua; Conghuang Li; Wei Hou; Honggang Zheng; Yanju Bao
Journal:  Evid Based Complement Alternat Med       Date:  2015-06-10       Impact factor: 2.629

2.  Liver resection versus transarterial chemoembolization for the treatment of intermediate-stage hepatocellular carcinoma.

Authors:  Shuling Chen; Huilin Jin; Zihao Dai; Mengchao Wei; Han Xiao; Tianhong Su; Bin Li; Xin Liu; Yu Wang; Jiaping Li; Shunli Shen; Qi Zhou; Baogang Peng; Zhenwei Peng; Sui Peng
Journal:  Cancer Med       Date:  2019-03-12       Impact factor: 4.452

3.  Association between Ambient Particulate Matter 2.5 Exposure and Mortality in Patients with Hepatocellular Carcinoma.

Authors:  Chern-Horng Lee; Sen-Yung Hsieh; Wen-Hung Huang; I-Kuan Wang; Tzung-Hai Yen
Journal:  Int J Environ Res Public Health       Date:  2019-07-12       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.